- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01029249
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
Oral HPV infection occurs at a higher rate among HIV-infected people than among the general population. Recent research in the United States and Europe has also found that HIV-infected people have a higher risk of oral and oropharyngeal squamous cell cancer than HIV-uninfected people. In one study, it was found that HPV seropositivity was associated with an increased risk of squamous cell carcinoma of the oropharynx (SCCOP). In addition to SCCOP, another HPV-related health concern is oral warts, a condition for which there is no effective treatment. Even after beginning treatment with highly active antiretroviral therapy (HAART), active HPV replication in the mouth and oropharynx may persist in HIV-infected people, leading to an increased risk of SCCOP and oral warts. The purpose of this study is to evaluate the frequency of oral HPV DNA shedding and oral warts in HIV-infected people prior to HAART initiation and at regular time points after HAART initiation.
ACTG A5257 is a study that is comparing the effectiveness of three non-nucleoside reverse transcriptase inhibitor (NNRTI)-sparing HAART regimens in treatment-naïve participants. This study will enroll participants from the ACTG A5257 study. Participants will attend a baseline study visit at the same time as their ACTG A5257 baseline study visit. At baseline and at Week 4, 16, 24, and 48 study visits, participants will undergo an examination of their mouth, throat wash and saliva collection, and behavioral questionnaires. A blood collection will also occur at Week 24.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
San Juan, Puerto Rico, 00931
- Puerto Rico-AIDS CRS (5401)
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35294-2050
- Alabama Therapeutics CRS (5801)
-
-
California
-
Los Angeles, California, Yhdysvallat, 90095
- UCLA CARE Center CRS (601)
-
Los Angeles, California, Yhdysvallat, 90033
- University of Southern California CRS (1201)
-
Palo Alto, California, Yhdysvallat, 94304
- Stanford
-
San Diego, California, Yhdysvallat, 92103
- Ucsd, Avrc Crs (701)
-
San Francisco, California, Yhdysvallat, 94110
- University of California San Francisco AIDS CRS (801)
-
-
Florida
-
Miami, Florida, Yhdysvallat, 33139
- University of Miami AIDS CRS (901)
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30308
- The Ponce de Leon Ctr. CRS (5802)
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Northwestern University CRS (2701)
-
Chicago, Illinois, Yhdysvallat, 60612
- Rush University Medical Center (2702)
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21201
- IHV Baltimore Treatment CRS (4651)
-
Boston, Maryland, Yhdysvallat, 02215
- Beth Israel Deaconess Medical Center ACTG CRS (103)
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Massachusetts General Hospital ACTG CRS (101)
-
-
Michigan
-
Detroit, Michigan, Yhdysvallat, 48202
- Henry Ford Hosp. CRS (31472)
-
-
Missouri
-
St. Louis, Missouri, Yhdysvallat, 63110
- Washington University CRS (2101)
-
-
New Jersey
-
Camden, New Jersey, Yhdysvallat, 08103
- Cooper Univ. Hosp. CRS (31476)
-
Newark, New Jersey, Yhdysvallat, 07103
- New Jersey Medical School- Adult Clinical Research Ctr. CRS
-
-
New York
-
New York, New York, Yhdysvallat, 10011
- Cornell CRS (7804)
-
New York, New York, Yhdysvallat, 10032
- HIV Prevention and Treatment
-
Rochester, New York, Yhdysvallat, 14642
- University of Rochester ACTG CRS (1101)
-
Rochester, New York, Yhdysvallat, 14607
- AIDS Care CRS (1108)
-
-
North Carolina
-
Chapel Hill, North Carolina, Yhdysvallat, 27514
- University of North Carolina AIDS CRS
-
Durham, North Carolina, Yhdysvallat, 27710
- Duke Univ. Med. Ctr. Adult CRS (1601)
-
Greensboro, North Carolina, Yhdysvallat, 27401
- Moses H. Cone Memorial Hosp. CRS
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45267
- University of Cincinnati CRS
-
Cleveland, Ohio, Yhdysvallat, 44106
- Case CRS (2501)
-
Cleveland, Ohio, Yhdysvallat, 44109
- MetroHealth CRS (2503)
-
Colombus, Ohio, Yhdysvallat, 43210
- The Ohio State University AIDS CRS (2301)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Hospital of the University of Pennsylvania CRS (6201)
-
-
Rhode Island
-
Providence, Rhode Island, Yhdysvallat, 02906
- The Miriam Hospital ACTG CRS (2951)
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37232
- Vanderbilt Therapeutics CRS (3652)
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Houston AIDS Research Team CRS (31473)
-
-
Virginia
-
Richmond, Virginia, Yhdysvallat, 23219
- Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98104
- University of Washington AIDS CRS (1401)
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Meet inclusion criteria for and be enrolled in ACTG A5257
- Ability and willingness of participant or legal guardian/representative to provide informed consent
Exclusion Criteria:
- Co-enrollment in A5260s
- Has begun receiving HAART as part of the A5257 study
- Has ever received an HPV vaccine or plans to receive an HPV vaccine in the 6 months after study entry
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: Kohortti
- Aikanäkymät: Tulevaisuuden
Kohortit ja interventiot
Ryhmä/Kohortti |
---|
ACTG A5257 participants
Participants in this study will also be enrolled in ACTG A5257.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
Type-specific oral HPV DNA shedding (presence versus absence)
Aikaikkuna: Measured at baseline (measured at pre-entry and entry into A5257) and at Weeks 16 and 24
|
Measured at baseline (measured at pre-entry and entry into A5257) and at Weeks 16 and 24
|
Persistence of same type HPV DNA shedding from pre-entry/baseline visits to Week 16 and 24 visits
Aikaikkuna: Measured at Weeks 16 and 24
|
Measured at Weeks 16 and 24
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
Clinical diagnosis (presence versus absence) of oral warts
Aikaikkuna: Measured at Weeks 16 and 24
|
Measured at Weeks 16 and 24
|
HPV shedding at one of the pre-HAART visits
Aikaikkuna: Measured at one of the pre-entry visits
|
Measured at one of the pre-entry visits
|
CD4 count change (compared to baseline)
Aikaikkuna: Measured at Weeks 4, 16, and 24
|
Measured at Weeks 4, 16, and 24
|
Plasma HIV-1 RNA suppression
Aikaikkuna: Measured at Weeks 4, 16, and 24
|
Measured at Weeks 4, 16, and 24
|
Quantitative changes in HPV DNA in oral specimens obtained from participants who have the same HPV subtypes at one of the two pre-HAART visits as well as at Week 16 or 24
Aikaikkuna: Measured at Weeks 16 or 24
|
Measured at Weeks 16 or 24
|
Clinical diagnosis (presence versus absence) or oral warts measured by a visual exam
Aikaikkuna: Measured at baseline and Weeks 16, 24, and 48
|
Measured at baseline and Weeks 16, 24, and 48
|
Number of oral sex partners in the last month
Aikaikkuna: Measured at baseline and Weeks 24 and 48
|
Measured at baseline and Weeks 24 and 48
|
Number of oral sex partners in the last 6 months
Aikaikkuna: Measured at baseline and Weeks 24 and 48
|
Measured at baseline and Weeks 24 and 48
|
Absolute CD8 count (obtained from A5257 study data)
Aikaikkuna: Measured at Weeks 0 and 24 in the A5257 study
|
Measured at Weeks 0 and 24 in the A5257 study
|
Absolute CD4 count (obtained from A5257 study data)
Aikaikkuna: Measured at Weeks 0, 24, and 48 in the A5257 study
|
Measured at Weeks 0, 24, and 48 in the A5257 study
|
Percentage and absolute number of CD4 cells that are interleukin (IL)-2+/interferon (IFN)+ or transforming growth factor (TGF)+ after HPV peptide stimulation measured from peripheral blood mononuclear cells (PBMCs)
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Percentage and absolute number of CD8 cells that are IFN, tumor necrosis factor (TNF), TGF+, or CD107+ after HPV peptide stimulation measured from PBMCs
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Percentage and absolute number of CD4 cells that are regulatory T cells (CD4+/CD25+/CD127low) measured from PBMCs
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Percentage of CD4 cells and CD8 cells that express CD38 and HLA-DR
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Persistence of HPV DNA of a specific type in throat wash specimens over the time course of the study
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Salivary total lgA and anti-HPV lgA and S-lgA titers
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Serum total anti-HPV lgG titers
Aikaikkuna: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Opintojen puheenjohtaja: Caroline Shiboski, DDS, MPH, PhD, Department of Orofacial Sciences, UCSF AIDS OHARA
- Opintojen puheenjohtaja: Mark A. Jacobson, MD, UCSF AIDS OHARA, Positive Health Program, San Francisco General Hospital
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- ACTG A5272
- 1U01AI068636 (Yhdysvaltain NIH-apuraha/sopimus)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset HIV-infektiot
-
Rabin Medical CenterRekrytointiCentral-line Associated Blood Stream Infections (CLABSI)Israel
-
Bactiguard ABKarolinska University HospitalValmisLeikkaus | Central Line Associated Blood Stream Infections (CLABSI)Ruotsi
-
Emory UniversityValmisCentral Line Associated Bloodstream Infections (CLABSI) | LuuydinsiirtoYhdysvallat
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrytointiHIV | HIV-testaus | HIV-yhteys hoitoon | HIV-hoitoYhdysvallat
-
University of MinnesotaPeruutettuHIV-infektiot | HIV/AIDS | Hiv | Aids | AIDS/HIV-ongelma | AIDS ja infektiotYhdysvallat
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University of Southampton ja muut yhteistyökumppanitRekrytointiHIV | HIV-testaus | Yhteys hoitoonEtelä-Afrikka
-
Hospital Clinic of BarcelonaValmisIntegraasi-inhibiittorit, HIV; HIV-PROTEAASIINHIBEspanja
-
Erasmus Medical CenterEi vielä rekrytointiaHIV-infektiot | Hiv | HIV-1-infektio | HIV I -infektioAlankomaat
-
University of Maryland, BaltimorePeruutettuHiv | Munuaissiirto | HIV-varasto | CCR5Yhdysvallat
-
National Taiwan UniversityRekrytointi